Key facts
- It has raised $14.6M; the latest was Early Stage VC in Apr 2026.
- Notable investors include CDBI Partners, Hubei Xiachuang Venture Capital Management, 1896 Capital, LAV (Lilly Asia Fund), Lepu Medical — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Yinghe Brain Science
- ·The full record, as it builds
Funding rounds
No funding rounds for Yinghe Brain Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yinghe Brain Science
Manufacturer of neuromodulation and brain-computer interface devices designed to address neurological disorders and advance clinical neuroscience applications. The company offers an integrated platform combining neural signal sensing, electrode and chip design, signal decoding, and stimulation technologies, enabling healthcare providers, research institutions, and neurotechnology developers to improve treatment precision and accelerate the development of advanced neurological therapies.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Yinghe Brain Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yinghe Brain Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yinghe Brain Science in its N-PORT filings yet. We sweep new filings monthly.